Effects of nitration on the structure and aggregation of alpha-synuclein.
Substantial evidence suggests that the aggregation of the presynaptic protein alpha-synuclein is a key step in the etiology of Parkinson's disease (PD). Although the molecular mechanisms underlying alpha-synuclein aggregation remain unknown, oxidative stress has been implicated in the pathogenesis of PD. Here, we report the effects of tyrosine nitration on the propensity of human recombinant alpha-synuclein to fibrillate in vitro. The properties of nitrated alpha-synuclein were investigated using a variety of biophysical and biochemical techniques, which revealed that nitration led to formation of a partially folded conformation with increased secondary structure relative to the intrinsically disordered structure of the monomer, and to oligomerization at neutral pH. The degree of self-association was concentration-dependent, but at 1 mg/mL, nitrated alpha-synuclein was predominantly an octamer. At low pH, small-angle X-ray scattering data indicated that the nitrated protein was monomeric. alpha-Synuclein fibrillation at neutral pH was completely inhibited by nitrotyrosination and is attributed to the formation of stable soluble oligomers. The presence of heparin or metals did not overcome the inhibition; however, the inhibitory effect was eliminated at low pH. The addition of nitrated alpha-synuclein inhibited fibrillation of non-modified alpha-synuclein at neutral pH. Potential implications of these findings to the etiology of Parkinson's disease are discussed.
Uversky
Vladimir N
VN
Department of Chemistry and Biochemistry, University of California, Santa Cruz, CA 95064, USA. enzyme@ucsc.edu
Yamin
Ghiam
G
Munishkina
Larissa A
LA
Karymov
Mikhail A
MA
Millett
Ian S
IS
Doniach
Sebastian
S
Lyubchenko
Yuri L
YL
Fink
Anthony L
AL
D000818:Animals; D002942:Circular Dichroism / Q000379:methods; D004305:Dose-Response Relationship, Drug; D006801:Humans; D018625:Microscopy, Atomic Force / Q000379:methods; D008855:Microscopy, Electron, Scanning / Q000379:methods; D008958:Models, Molecular; D009419:Nerve Tissue Proteins / Q000737:chemistry / Q000378:metabolism* / Q000648:ultrastructure; D016877:Oxidants / Q000494:pharmacology*; D011994:Recombinant Proteins / Q000737:chemistry / Q000187:drug effects / Q000378:metabolism / Q000648:ultrastructure; D013052:Spectrometry, X-Ray Emission / Q000379:methods; D017550:Spectroscopy, Fourier Transform Infrared / Q000379:methods; D013057:Spectrum Analysis / Q000379:methods; D022502:Stress Fibers / Q000187:drug effects / Q000378:metabolism / Q000648:ultrastructure; D051843:Synucleins; D013774:Tetranitromethane / Q000494:pharmacology*; D013997:Time Factors; D014443:Tyrosine / Q000378:metabolism; D051844:alpha-Synuclein
D009419:Nerve Tissue Proteins; D016877:Oxidants; D011994:Recombinant Proteins; C497604:SNCA protein, human; D051843:Synucleins; D051844:alpha-Synuclein; D014443:Tyrosine; D013774:Tetranitromethane